Clinical Trials
2 trialsPhase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Pharmaceutical Preparations × Clear all
NCT03076437 2021-03-19
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Institute for Innovation and Translational Medicine
Phase 1/2 Completed
NCT03191773 2017-06-20
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Unknown